Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 10/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.35 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.34 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29567101 | 0.84 | NR3C1 (0.41) | FFAR1NR3C1FFAR4 | |
| SCHEMBL24309585 | 0.84 | NR3C1 (0.41) | FFAR1NR3C1FFAR4 | |
| SCHEMBL24298137 | 0.84 | GPR39 (0.35) | CYP1A2 | |
| SCHEMBL24309590 | 0.82 | FFAR1 (0.37) | FFAR1NR3C1FFAR4CYSLTR2CYSLTR1 | |
| SCHEMBL24330885 | 0.79 | TDP1 (0.34) | — | |
| SCHEMBL24330884 | 0.76 | F10 (0.40) | NR1H4PPARG | |
| SCHEMBL24310009 | 0.76 | GPR39 (0.45) | CYP1A2 | |
| SCHEMBL24309643 | 0.73 | FFAR1 (0.33) | FFAR1 | |
| SCHEMBL24309507 | 0.72 | CYP1A2 (0.35) | CYP1A2 | |
| SCHEMBL24326406 | 0.70 | SYK (0.40) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076626-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |